Semaglutide and alcohol consumption
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviours, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD) (1):
- in animal models, the GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission
In a retrospective cohort study of electronic health records of 83,825 patients with obesity (2):
- was shown that semaglutide (compared with other anti-obesity medications) was associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period
- consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes
- similar findings were replicated in the study population with 598,803 patients with type 2 diabetes
Reference:
- Chuong V et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023 Jun 22;8(12):e170671.
- Wang, W., Volkow, N.D., Berger, N.A. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun15, 4548 (2024)
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.